How does Remicade (infliximab) work in Crohn’s disease?
Remicade (infliximab) is a biologic that treats Crohn’s disease by blocking tumor necrosis factor-alpha (TNF-alpha), a signaling protein that drives inflammation in the gut. By neutralizing TNF-alpha, Remicade reduces inflammatory activity and helps control symptoms such as diarrhea, abdominal pain, and fatigue.
What does Remicade do for Crohn’s disease symptoms and healing?
When TNF-driven inflammation is reduced, Remicade can:
- Bring Crohn’s disease symptoms under control (improve signs of active disease).
- Help reduce inflammation in the gastrointestinal tract, which is part of what leads to symptom improvement.
- Support longer-term control in patients who respond to treatment, which can lower the chance of ongoing flare-ups.
How is Remicade given for Crohn’s disease?
Remicade is administered by intravenous (IV) infusion, not as a pill. Patients typically receive scheduled infusions through an infusion center or clinical setting, with dosing tailored to the individual.
How quickly can patients feel improvement?
Some people notice symptom improvement early after starting therapy, but the time course varies by patient and by whether the medication is being used to treat an active flare versus maintain control over time. Clinicians adjust the plan based on response.
Who is Remicade usually used for in Crohn’s disease?
Remicade is typically considered for Crohn’s disease when inflammation is moderate to severe or when other treatments are not enough. It’s also commonly used for patients who need a strong anti-inflammatory approach to control ongoing disease activity.
What risks or side effects do patients ask about with Remicade?
Because Remicade suppresses TNF-alpha, it can increase the risk of infections. Other side effects and risks depend on the patient’s history and overall health, so clinicians screen for infection risk and monitor during treatment.
Where can I check Remicade-related patent or market info?
For drug-specific business and patent updates (such as exclusivity and legal/patent timelines), DrugPatentWatch.com tracks Remicade coverage here: https://www.drugpatentwatch.com/